Abstract:Objective:To evaluate the results of neuroblastoma (NB) based upon risk-adapted therapy.Methods:From September 2002 to December 2018, clinical data were reviewed for 483 newly diagnosed NB patients aged ≤18 years based on risk-adapted therapy. They were stratified into low, intermediate and high-risk groups by age, stage, histological category and MYCN status. There were 290 males and 193 females with a median diagnostic age of 3.5 years (7 days to 18 years). The stages were 1 (n=19) , 2 (n=25) , 3 (n=95) , 4 (n=334) and 4S (n=10). Surgery alone or surgery plus low intensive chemotherapy for low-risk group (n=46, 9.5%) ; Surgery plus moderate intensive chemotherapy with or without radiotherapy for intermediate-risk group (n=102, 21.1%) ; For high-risk group (n=335, 69.4%) , before 2013, the treatment strategies included 8 cycles of alternating chemotherapy of cyclophosphamide (CTX) + vincristine (VCR) + pirarubicin (THP) and cisplatin (DDP) + etoposide (VP16) , surgery, with or without autologous hematopoietic stem cell transplantation (ASCT) , radiotherapy, with or without biotherapy and isotretinoin maintenance therapy for 1 year; after 2013, 8 cycles of alternating chemotherapy of CTX + VCR + THP and VP16 + ifosfamide + DDP protocol, surgery, radiotherapy, with or without biological therapy and oral maintenance chemotherapy drugs for 1 year. Recurrent patients received salvage therapy.Results:MYCN amplification was 22.4 % (72/322) in all groups and 33.8%(72/213) in high-risk group. ASCT was performed for only 15 cases. During a median follow-up period of 38(2.5-208) months, 3-year event-free survival (EFS) and overall survival (OS) were (86.5±5.1) % and 100% for low-risk group ; (79.1±4.3)% and (89.2±3.3) % for intermediate-risk group ; (30.6±2.7)% and (60.3±2.9)% for high-risk group respectively. Univariate survival analysis of 335 high-risk patients indicated that stage 4 and chemotherapy alone were poor prognostic factors for EFS/OS. Multivariate survival analysis showed that stage 4 and chemotherapy alone were independent adverse prognostic factors for EFS in high-risk NB patients while stage 4, chemotherapy alone and primary abdominal lesions were independent adverse prognostic factors for OS in high-risk NB patients. The 3-year EFS for MYCN positive high-risk patients was (27.4±6.3) % and for MYCN negative high-risk patients (36.7±4.4) % and the inter-group difference was statistically significant ( P=0.049). The 3-year EFS for MYCN positive high-risk patients with stage 4 was (18.7±6.7) % and for MYCN positive high-risk patients with stage 3/4S was (49.4±13.1) % and the inter-group difference was statistically significant ( P=0.009). In high-risk complete/partial remission patients without ASCT, 3-year EFS of oral isotretinoin maintenance therapy was (28.0±5.1)% while 3- year EFS of oral chemotherapy maintenance therapy was (42.1±5.1)% and the inter-group difference was statistically significant ( P=0.019). In high-risk patients, 3-year EFS for the therapeutic model of chemotherapy + surgery + radiotherapy was 37.1% , 19.0% for chemotherapy + surgery and 7.7% for chemotherapy alone. And the inter-group differences were statistically significant ( P<0.001). The 3-year EFS in high-risk group was (21.5±4.1 ) % before 2013 and (34.9±3.6) % after 2013. And the inter-group difference was statistically significant ( P=0.004) ; 3- year OS in high-risk group was (47.7±4.9)% before 2013 and (66.7±3.6) % after 2013. And the inter-group difference was statistically significant ( P<0.001). Conclusions:NB may be stratified into low, intermediate and high-risk groups based upon age, stage, histological category and MYCN status. For risk-adapted therapy, low and intermediate groups have better survival. High-risk patients have poor survival and new therapy should be explored. Salvage therapy for recurrent NB offers a survival benefit.

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification

Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era

MYCN amplification and International Neuroblastoma Risk Group stratification on fine-needle aspiration biopsy and their correlation to survival in neuroblastoma

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma

Clinical Evaluation of Integrated Panel Testing by Next-Generation Sequencing for Somatic Mutations in Neuroblastomas with Mycn Unamplification

MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma

Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis

Outcome analysis of neuroblastoma based upon risk-adapted therapy: a report of 483 cases

Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival

Predicting amplification of MYCN using CpG methylation biomarkers in neuroblastoma

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis